X
Innovation

BrainScope eyes U.K. for traumatic brain injury device

BrainScope, a medical neurotechnology company with an impressive list of venture capital backers, said Tuesday that it plans to introduce its Ahead EU-100, a device that can assess head injuries, in the United Kingdom.
Written by Larry Dignan, Contributor

BrainScope, a medical neurotechnology company with an impressive list of venture capital backers, said Tuesday that it plans to introduce its Ahead EU-100, a device that can assess head injuries, in the United Kingdom.

The idea behind the product is to give physicians a handheld tool that can assess patients with traumatic brain injuries as well as concussions. BrainScope had previously indicated that it was entering the United Kingdom via a clinical trial in emergency rooms.

According to BrainScope, the Ahead EU-100 is in development. The device is radiation free, non-invasive tool that measures electrical brain activity and highlights the patterns associated with brain injuries. The Ahead EU-100 has a handheld device armed with software and algorithms and an electrode headset. The patient data can also be centralized on the Web.

BrainScope said it plans to form a U.K. subsidiary to navigate the national health system and work with researchers and hospitals. The company is based in Bethesda, MD. The company's clinical trial will start in the late Spring and the company expects European regulatory clearance in the second half of 2011. Another tool to measure brainwaves, the Zoom-100DC, was cleared by European regulators and the Food and Drug Administration in the U.S.

The company is backed by Revolution LCC, created by Steve Case, Alafi Capital, Brain Trust Accelerator Fund, Draper Fisher Jurvetson, Portage Ventures and ZG Ventures.

Given the attention to brain injuries---especially among athletes playing American football---BrainScope could have a nice market niche ahead.

Related:

This post was originally published on Smartplanet.com

Editorial standards